ライフサイエンスコーパス: xerostomia

1 (keratoconjunctivitis sicca) and dry mouth (xerostomia).

2 cal trial in patients with radiation-induced xerostomia.

3 options for the patient with DM experiencing xerostomia.

4 benefit for management of radiation-induced xerostomia.

5 y presents as keratoconjunctivitis sicca and xerostomia.

6 y glands cause reduced salivation leading to xerostomia.

7 s also experienced subjective improvement in xerostomia.

8 sparing IMRT reduces the incidence of severe xerostomia.

9 dissection pain and dysfunction, as well as xerostomia.

10 of grade 3 xerostomia, and none had grade 4 xerostomia.

11 weight loss, disfigurement, depression, and xerostomia.

12 maging saliva production and contributing to xerostomia.

13 Amifostine reduced acute and chronic xerostomia.

14 development of hyposalivation in DM-induced xerostomia.

15 recently in the scintigraphic evaluation of xerostomia.

16 esophagus, 4.7%; mucous membranes, 3.1%; and xerostomia, 3.1%.

17 Toxicities were mild, with rash (90%) and xerostomia (54%) being most frequent.

18 Xerostomia, a secondary end point, was assessed using th

19 ure produced greater improvement in reported xerostomia (adjusted difference in Xerostomia Inventory

20 ar posttreatment, 61% of patients had severe xerostomia and 47% had compromised swallowing.

21 ead and neck cancer causes acute and chronic xerostomia and acute mucositis.

22 documented adverse effects, most common are xerostomia and cheilitis.

23 Late complications of treatment included xerostomia and hoarseness.

24 the physiological mechanisms associated with xerostomia and hyposalivation.

25 IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and

26 The prevalence of xerostomia and salivary gland hypofunction appears to be

27 ell counts are significantly associated with xerostomia and salivary gland hypofunction in a populati

28 The association of xerostomia and salivary gland hypofunction with HIV infe

29 r =3 acute mucositis, and grade > or =2 late xerostomia and were based on the worst toxicity reported

30 Complaints of a dry mouth (xerostomia) and sialoadenitis are frequent side effects

31 ], (2) salivary dysfunction (saliva flow and xerostomia), and (3) maximum mouth-opening measurement.

32 Only two patients complained of grade 3 xerostomia, and none had grade 4 xerostomia.

33 Swallowing abnormalities, xerostomia, and poor dentition may result in dietary ada

34 [eNOS]) are altered in the onset of diabetic xerostomia; and 2) to determine whether the changes in n

35 Xerostomia as a result of salivary gland damage is a per

36 The rate of grade 2 xerostomia at 1 year from start of IMRT was 13.5%.

37 in 73 of 82 alive patients; grade 2 or worse xerostomia at 12 months was significantly lower in the I

38 proportion of patients with grade 2 or worse xerostomia at 12 months, as assessed by the Late Effects

39 In clinical application, severe xerostomia became the dose-limiting toxicity if treatmen

40 d to mild transient bone marrow toxicity and xerostomia because of uptake of the small-molecule agent

41 common toxicity 6 months after treatment was xerostomia, but this occurred in 3% or less of patients

42 Xerostomia can be caused by medications, chronic disease

43 Xerostomia can eventually lead to difficulty in swallowi

44 to reduce the salivary symptoms of pain and xerostomia caused by 131I therapy for papillary and foll

45 and composition alterations, development of xerostomia, characteristics of patients at risk for sali

46 Any candidates with subjective xerostomia, conditions or medications associated with dr

47 filtration of exocrine tissues, resulting in xerostomia (dry mouth) and keratoconjunctivitis sicca (d

48 the salivary and lacrimal glands leading to xerostomia (dry mouth) and xerophthalmia (dry eyes).

49 patients that suffer from chronic dry mouth (xerostomia) due to salivary gland injury from radiation

50 appeared to reduce mucositis, dysphagia, and xerostomia during hyperfractionated radiotherapy (n = 40

51 for the millions of patients who suffer from xerostomia each year.

52 Amifostine reduced grade > or =2 acute xerostomia from 78% to 51% (P<.0001) and chronic xerosto

53 stomia from 78% to 51% (P<.0001) and chronic xerostomia grade > or = 2 from 57% to 34% (P=.002).

54 hortened (5 v 26 days), and the incidence of xerostomia grade >/= 2 was lower (67% v 80%), favoring p

55 ncluded the incidence of grade > or =2 acute xerostomia, grade > or =3 acute mucositis, and grade > o

56 Except for mild reversible xerostomia in 2 patients, no long-term side effects were

57 The most prevailing cause of xerostomia in elderly persons is the use of anticholiner

58 lved acute inflammation and SMG dysfunction (xerostomia) in response to LPS that is similar to human

59 reported xerostomia (adjusted difference in Xerostomia Inventory = -5.8; 95% CI, -0.9 to -10.7; P =

60 ions in salivary flow rate, composition, and xerostomia inventory score were analyzed.

61 urthermore, patients completed the validated xerostomia inventory.

62 secondary end point, was assessed using the Xerostomia Inventory.

63 Xerostomia is defined as dry mouth resulting from a chan

64 Studies have shown that xerostomia is more common in females at the onset of DM.

65 Because xerostomia is one of the most important clinical feature

66 Xerostomia is the most common late side-effect of radiot

67 s were seen between randomised groups in non-xerostomia late toxicities, locoregional control, or ove

68 saliva, a reduction in salivary flow (as in xerostomia) may diminish the oral self-defense mechanism

69 ute adverse effects were associated with RT (xerostomia, mucositis, and local skin toxicity).

70 (n = 10), advanced age (n = 7), concern for xerostomia (n = 4), or patient refusal (n = 2).

71 Xerostomia, nausea, and fatigue occurred sporadically (<

72 Xerostomia occurred in 8%.

73 None of these individuals had subjective xerostomia or dry eyes.

74 Xerostomia, or dry mouth, is a common side effect of hea

75 the prevalence of sialadenitis, stomatitis, xerostomia, or dysgeusia over the next 6 mo (P > 0.05).

76 us elders (N = 133) and a clinical sample of xerostomia patients (N = 85).

77 sea, hot flashes, fatigue, radiation-induced xerostomia, prolonged postoperative ileus, anxiety/mood

78 submandibular/sublingual saliva samples and xerostomia questionnaire responses were collected.

79 se, refers to keratoconjunctivitis sicca and xerostomia resulting from immune lymphocytes that infilt

80 e (SS) is characterized by xerophthalmia and xerostomia resulting from loss of secretory function due

81 racterized by keratoconjunctivitis sicca and xerostomia resulting from lymphocytic infiltrates of the

82 All subjects had normal oral exams, xerostomia scores and unstimulated whole-mouth salivary

83 At 12 months xerostomia side-effects were reported in 73 of 82 alive

84 such an effect could underlie the dry mouth (xerostomia) that occurs as an unexplained side-effect of

85 Current xerostomia therapies only provide temporary symptom reli

86 Xerostomia was assessed based on "yes" responses to a dr

87 Confirmation of xerostomia was determined by increased water intake and

88 At 24 months, grade 2 or worse xerostomia was significantly less common with IMRT than

89 Xerostomia was the only mentionable clinical side effect

90 Minimal grade 3 and lack of grade 4 xerostomia were encouraging.

91 ificant reductions in pain, dysfunction, and xerostomia were observed in patients receiving acupunctu

92 reasonable), and to decrease acute and late xerostomia with fractionated radiation therapy alone for

93 ncer, which showed reduced acute and chronic xerostomia with preserved antitumour response, some inst

94 iness with TCAs, SNRIs, and anticonvulsants; xerostomia with TCAs; and peripheral edema and burning s

95 ed with lacrimal dysfunction (P = 0.010) and xerostomia with xerophthalmia (r = 0.32, P = 0.001); and